The restricted expression of CD74 by normal tissues and its very rapid internalization make CD74 an attractive therapeutic target for both cancer and immunologic diseases. It has also been shown to have value as a gastric carcinoma marker.
| Inventor | Institute |
|---|---|
| Roy Jefferis | University of Birmingham |
| SKU: | 151438 |
|---|---|
| Product description: | HLA-DR-associated invariant chain (CD74) plays a role in antigen presentation. In addition to its expression on antigen-presenting cells, CD74 is expressed by carcinomas of renal, lung, gastric, and thymic origin and by certain sarcomas. The restricted expression of CD74 by normal tissues and its very rapid internalization make CD74 an attractive therapeutic target for both cancer and immunologic diseases. It has also been shown to have value as a gastric carcinoma marker. |
| Alternate name: | CD74 Molecule; HLA-DR Antigens-Associated Invariant Chain; Gamma Chain Of Class II Antigens; Ia-Associated Invariant Chain; MHC HLA-DR Gamma Chain; DHLAG; P33; CD74 Antigen; Ia-GAMMA; HLADG |
| Conjugation: | Unconjugated |
| Isotype: | IgM |
| Immunogen: | HFB1 plasmacytoid cell line |
| Myeloma used: | NS0 |
| Cat. #: | 151438 |
|---|---|
| Tool sub type: | Primary antibody |
| Unit size: | 100 ug |
| Research Fields: | Immunology |
| Application: | FACS ; IHC ; IP ; RIA |
| Target: | Human Leukocyte Antigen-DR locus (HLA-DR) associated invariant chain (CD74) |
| Reactivity: | Human |
| Clone: | BU43 |
| Host: | Mouse |
| Class: | Monoclonal |
| Target background: | HLA-DR-associated invariant chain (CD74) plays a role in antigen presentation. In addition to its expression on antigen-presenting cells, CD74 is expressed by carcinomas of renal, lung, gastric, and thymic origin and by certain sarcomas. The restricted expression of CD74 by normal tissues and its very rapid internalization make CD74 an attractive therapeutic target for both cancer and immunologic diseases. It has also been shown to have value as a gastric carcinoma marker. |
|---|
| Format: | Liquid |
|---|---|
| Concentration: | 0.9-1.1 mg/ml |
| Storage buffer: | PBS with 0.02% azide |
| Storage conditions: | -15° C to -25° C |
| Shipping conditions: | Dry ice |
| References: |
Gregers et al. 2003. Int Immunol. 15(11):1291-9. PMID: 14565927. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation. Nordeng et al. 2002. Mol Biol Cell. 13(6):1846-56. PMID: 12058053. The cytoplasmic tail of invariant chain regulates endosome fusion and morphology. Nordeng et al. 1999. J Biol Chem. 274(30):21139-48. PMID: 10409667. Overexpression of proteins containing tyrosine- or leucine-based sorting signals affects transferrin receptor trafficking. Moldenhauer et al. 1999. Immunology. 96(3):473-84. PMID: 10233730. Surface-expressed invariant chain (CD74) is required for internalization of human leucocyte antigen-DR molecules to early endosomal compartments. Rudy et al. 1997. J Immunol. 158(5):2116-25. PMID: 9036956. The nonpolymorphic MHC class II isotype, HLA-DQA2, is expressed on the surface of B lymphoblastoid cells. Koch et al. 1991. J Immunol. 147(8):2643-51. PMID: 1918985. Rapid intracellular pathway gives rise to cell surface expression of the MHC class II-associated invariant chain (CD74). Wraight et al. 1990. J Biol Chem. 265(10):5787-92. PMID: 1690714. Human major histocompatibility complex class II invariant chain is expressed on the cell surface. |
|---|
| Cat. # | Tool Name | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 151024 | Anti-Hairy [1/24] |
Key Info
Anti-Hairy [1/24]
|
View Tool | |||||||||||||||||||
| 151034 | Anti-HSVUL42 [13D11] |
Key Info
Anti-HSVUL42 [13D11]
|
View Tool | |||||||||||||||||||
| 151029 | Anti-HSVICP8 [11E2] |
Key Info
Anti-HSVICP8 [11E2]
|
View Tool | |||||||||||||||||||
| 151035 | Anti-CD8 [14] mAb |
Key Info
Anti-CD8 [14] mAb
|
View Tool | |||||||||||||||||||
| 151018 | Anti-Mos [R38.1] |
Key Info
Anti-Mos [R38.1]
|
View Tool | |||||||||||||||||||
Please note we may take up to three days to respond to your enquiry.
CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.